Show simple item record

dc.contributor.authorSahay, Arvind
dc.contributor.authorJaikumar, Saravana
dc.date.accessioned2018-02-07T11:59:40Z
dc.date.available2018-02-07T11:59:40Z
dc.date.issued2016-02-09
dc.identifier.urihttp://hdl.handle.net/11718/20284
dc.description.abstractIn this paper, we empirically examine whether price regulation of generic essential drugs in India results in social welfare (in terms of increase in sales volume post regulation). In 2013, the Indian government enacted the Drug Price Control (DPCO) which regulated the prices of essential medicines. Using historical monthly sales volume data, we identify the best fitting SARIMA (seasonal auto regressive integrated moving average) model for each of the 105 oral solid molecules included in DPCO 2013. Using these models and following the event study approach we statistically compare the baseline against the actual volume during event window. We find that while DPCO resulted in an increase in sales volume for few molecules, overall the regulation has resulted in a reduction in sales volume. On further analysis, we find that increasing the detailing efforts for molecules with high percentage sales in urban and semi-urban cities may likely result in positive DPCO impact. Our findings have significant policy and marketing implications.en_US
dc.language.isoen_USen_US
dc.publisherIndian Institute of Management Ahmedabaden_US
dc.relation.ispartofseriesW.P.;2016-02-01
dc.subjectPharmaceutical industryen_US
dc.subjectDrug price controlen_US
dc.subjectDrug Price Control Orderen_US
dc.titleDoes pharmaceutical price regulation result in greater access to essential medicines? study of the impact of drug price control order on sales volume of drugs in indiaen_US
dc.typeWorking Paperen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record